New Study: Strut-based Brachytherapy is Effective Treatment for Early-Stage Breast Cancer
Cianna Medical, Inc.: Researchers from 12 sites report favorably low recurrence rates and minimal toxicities.
CHICAGO (PRWEB) May 02, 2013
Strut-based breast brachytherapy — a form of radiation therapy for early-stage breast cancer — has been shown to be a well-tolerated, effective treatment, according to a scientific poster presentation at the 2013 annual meeting of the American Society of Breast Surgeons (ASBrS) in Chicago, May 1-5, 2013.
The multi-institutional study, which looked at 320 patients with a median of three years of follow up, found favorably low rates of breast cancer recurrence with minimal acute and few adverse late toxicities. All patients received accelerated partial breast irradiation (APBI) with the SAVI® (Strut-Adjusted Volume Implant) applicator.
“With 10 years of data supporting its efficacy and safety, breast brachytherapy is an option for many women with early-stage breast cancer,” said lead author and breast surgeon Kerri Perry, MD, FACS. “The strut-based applicator´s unique ability to precisely target radiation while sparing healthy tissues not only improves cosmetic outcomes, but also expands the number of women who are candidates for breast brachytherapy.”
Toxicities at any time post-treatment were low in both incidence and grade, including hyperpigmentation (0.3%), fat necrosis (0.9%), telangiectasia (2.2%), and symptomatic seroma (2.5%). According to the researchers, these compare favorably to rates reported in studies of other forms breast brachytherapy.
The study also reported a cancer recurrence rate of just 0.61%, which is less than the recurrence rate reported in the literature for whole-breast irradiation, which takes six weeks and is the traditional form of radiotherapy for early-stage breast cancer.
“Strut-based brachytherapy is an ideal option for eligible patients, as it provides them with a course of radiation that will control their cancer while minimizing exposure to healthy tissue and significantly reducing treatment time compared to whole breast radiation,” said co-author and breast surgeon Deanna Attai, MD, FACS.
Data for the study was drawn from the ongoing work of the SAVI Collaborative Research Group. The group was established to study the long-term outcomes of APBI treatment with the SAVI device.
Strut-based brachytherapy delivers a shortened course of radiation therapy for early-stage breast cancer patients following lumpectomy surgery. The strut-based, open architecture design allows physicians to sculpt radiation based on patient-specific anatomy, which increases the number of women who can benefit from APBI. Clinical studies show that by providing targeted radiation where it is needed most, the risks of toxicity and cosmetic side effects are reduced.
This radiation treatment is part of breast conservation therapy, which includes lumpectomy— the surgical removal of the cancerous tissue within the breast plus tissue immediately around the tumor — followed by radiation. This approach is an alternative to mastectomy, which removes the entire breast and is often followed by breast reconstruction.
Radiation treatment after a lumpectomy has traditionally involved irradiation of the entire breast with an external beam. Besides the inconvenience of the six-week-long regimen, many women must travel some distance to receive external-beam radiation. That can put additional stress on their families, jobs, and financial resources.
About Cianna Medical, Inc.
Cianna Medical, Inc. is a medical device company focused on women’s health and dedicated to the innovative treatment of early-stage breast cancer. The company manufactures and markets the SAVI breast brachytherapy applicator, for the delivery of radiation after lumpectomy surgery. The applicator allows precise sculpting of the radiation dose, and is designed to make the benefits of accelerated partial breast irradiation available to a greater number of women.
For more information, call (toll-free) 866-920-9444 or visit http://www.ciannamedical.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/5/prweb10694475.htm